DE3785102T2 - Verfahren zur herstellung von faktor-viii:c-typ-proteinen. - Google Patents

Verfahren zur herstellung von faktor-viii:c-typ-proteinen.

Info

Publication number
DE3785102T2
DE3785102T2 DE8787900933T DE3785102T DE3785102T2 DE 3785102 T2 DE3785102 T2 DE 3785102T2 DE 8787900933 T DE8787900933 T DE 8787900933T DE 3785102 T DE3785102 T DE 3785102T DE 3785102 T2 DE3785102 T2 DE 3785102T2
Authority
DE
Germany
Prior art keywords
factor viii
type proteins
producing factor
phospholipid
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787900933T
Other languages
English (en)
Other versions
DE3785102D1 (de
Inventor
J Kaufman
Robert Adamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27124021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3785102(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE3785102D1 publication Critical patent/DE3785102D1/de
Publication of DE3785102T2 publication Critical patent/DE3785102T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE8787900933T 1986-01-03 1987-01-02 Verfahren zur herstellung von faktor-viii:c-typ-proteinen. Expired - Lifetime DE3785102T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81603186A 1986-01-03 1986-01-03
US94233886A 1986-12-16 1986-12-16
PCT/US1987/000033 WO1987004187A1 (en) 1986-01-03 1987-01-02 METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS

Publications (2)

Publication Number Publication Date
DE3785102D1 DE3785102D1 (de) 1993-05-06
DE3785102T2 true DE3785102T2 (de) 1993-07-22

Family

ID=27124021

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787900933T Expired - Lifetime DE3785102T2 (de) 1986-01-03 1987-01-02 Verfahren zur herstellung von faktor-viii:c-typ-proteinen.

Country Status (8)

Country Link
EP (1) EP0253870B1 (de)
JP (1) JP2525022B2 (de)
AT (1) ATE87663T1 (de)
DE (1) DE3785102T2 (de)
DK (1) DK457587A (de)
FI (1) FI873796A0 (de)
NO (1) NO873679L (de)
WO (1) WO1987004187A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
AU606925B2 (en) * 1987-01-30 1991-02-21 Biogen, Inc. A method for producing factor viii in high yield
CA1331157C (en) * 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
DE69012601T2 (de) * 1989-02-02 1995-01-19 Joel S Greenberger Gentherapie durch stützgewebebezügliche Zellen.
US7247475B2 (en) 1989-07-28 2007-07-24 Wyeth Method for producing monoclonal antibodies
US6475787B1 (en) 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
ATE319817T1 (de) 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
DE69722639T2 (de) 1996-09-24 2004-04-29 The Procter & Gamble Company, Cincinnati Stabilisierte proteine mit protease-inhibitorfunktion und varianten davon
EP1062244B1 (de) 1998-03-12 2002-08-28 Genetics Institute, LLC Verbessertes verfahren zur herstellung von faktor viii
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
CZ303929B6 (cs) 2000-03-22 2013-07-03 Octapharma Biopharmaceuticals Gmbh Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2520586A1 (de) 2006-06-30 2012-11-07 The Regents of the University of Michigan Verfahren zur Herstellung von Faktor-VIII-Proteinen durch Rekombinationsverfahren
EP1988101A1 (de) 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
PT2393828T (pt) 2009-02-03 2017-01-18 Amunix Operating Inc Polipéptidos recombinantes estendidos e composições que compreendem os mesmos
JP5813641B2 (ja) 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
PL3326643T3 (pl) 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
NZ605400A (en) 2010-07-09 2015-05-29 Biogen Idec Hemophilia Inc Chimeric clotting factors
EP2957628A1 (de) 2010-10-05 2015-12-23 Novo Nordisk Health Care AG Verfahren zur proteinherstellung
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
DK3513804T3 (da) 2011-07-08 2022-06-20 Bioverativ Therapeutics Inc Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf
EP2737311B1 (de) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Tests zur überwachung von blutungsstörungen
SG11201403764XA (en) 2012-01-12 2014-07-30 Biogen Idec Inc Chimeric factor viii polypeptides and uses thereof
SI2802668T1 (sl) 2012-01-12 2019-01-31 Bioverativ Therapeutics Inc. Zmanjšanje imunogeničnosti proti faktorju VIII pri posameznikih, ki se zdravijo zaradi faktorja VIII
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
EP3693000B1 (de) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Prokoagulatorische verbindungen
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
NZ703366A (en) 2012-07-11 2018-03-23 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
EP3970738A1 (de) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blutfaktorüberwachungstest und verwendungen davon
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (de) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
PL2956477T3 (pl) 2013-02-15 2021-06-14 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
WO2014144795A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor viii polypeptide formulations
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
EP3875106A1 (de) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
EP4332839A2 (de) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Pharmakokinetische werkzeuge für populationen und verwendungen davon
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
JP6609561B2 (ja) 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN104630131B (zh) * 2015-01-15 2017-08-15 上海交通大学 一种稳定表达人凝血八因子的cho细胞株及其应用
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US11753461B2 (en) 2016-02-01 2023-09-12 Bioverativ Therapeutics Inc. Optimized factor VIII genes
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
CA3072334A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
RU2020114616A (ru) 2017-09-27 2021-10-28 Сайджилон Терапьютикс, Инк. Способы, композиции и имплантируемые элементы, содержащие активные клетки
JP2021512126A (ja) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
US20190375822A1 (en) 2018-05-18 2019-12-12 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CN113227385A (zh) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US10654911B1 (en) * 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
CN114007637A (zh) 2019-06-19 2022-02-01 比奥维拉迪维治疗股份有限公司 用于治疗血友病和低骨矿物质密度的重组因子viii-fc
IL310997A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813389A (ja) * 1981-07-16 1983-01-25 Kyowa Hakko Kogyo Co Ltd 細胞培養用培地
JPS5823784A (ja) * 1981-08-04 1983-02-12 Ajinomoto Co Inc 哺乳動物細胞用培地
JPS5913389A (ja) * 1982-07-14 1984-01-24 Matsushita Electric Ind Co Ltd 炭酸ガスレ−ザ発振器
GB2129685B (en) * 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
JPS59166079A (ja) * 1983-03-14 1984-09-19 Morinaga & Co Ltd 細胞培養用培地
JPS59173078A (ja) * 1983-03-22 1984-09-29 Morinaga & Co Ltd 細胞培養用培地
WO1985001961A1 (en) * 1983-10-28 1985-05-09 Genetics Institute Production of factor viii and related products
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
DE3769872D1 (de) * 1986-07-11 1991-06-13 Miles Inc Herstellung von rekombinantem protein.

Also Published As

Publication number Publication date
NO873679L (no) 1987-11-02
JP2525022B2 (ja) 1996-08-14
DK457587A (da) 1987-11-02
EP0253870A4 (de) 1988-10-20
FI873796A (fi) 1987-09-01
DE3785102D1 (de) 1993-05-06
ATE87663T1 (de) 1993-04-15
EP0253870A1 (de) 1988-01-27
FI873796A0 (fi) 1987-09-01
DK457587D0 (da) 1987-09-02
EP0253870B1 (de) 1993-03-31
WO1987004187A1 (en) 1987-07-16
JPS63502318A (ja) 1988-09-08
NO873679D0 (no) 1987-09-02

Similar Documents

Publication Publication Date Title
DE3785102D1 (de) Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
ATE124725T1 (de) Verbessertes verfahren zur herstellung von faktor viii:c-typ-proteinen.
FI852547L (fi) Framstaellning av faktor viii och daertill hoerande produkter.
ATE342357T1 (de) Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle
DE3752372D1 (de) Verfahren zur regulierung der metabolischen stabilität von proteinen
ES2088858T3 (es) Proteina interleuquina-4 que tiene actividad de factor de crecimiento de celulas b(bcgf) y de factor de crecimiento de celulas t(tcgf) en celulas humanas (interleuquina-4 humana).
FI820075L (fi) Rekombination-dna-medel och foerfarande
DE59608743D1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
AU4159185A (en) Method of inhibiting binding of von willebrand factor to human platelets and inducing interaction of platelets with vessel walls
ATE334146T1 (de) Verfahren zur herstellung von erythropoietin frei von tierischen proteinen
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
DE3382837T2 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
US5043429B1 (en) Protein fragments containing factor VIII binding domain of von willebrand factor
DE3587377D1 (de) Verfahren zur herstellung von halbleiteranordnungen unter verwendung von silizium-auf- isolator techniken.
ATE69108T1 (de) Elektrophoretisches gel hoher aufloesung sowie methode zur abscheidung von serumproteinen.
DE3886292D1 (de) Expressionsvektoren und Verfahren unter deren Verwendung zur Gewinnung von Cro/beta-Galaktosidase/PTH-Fusionsproteinen und von PTH.
DE69425809D1 (de) Methoden zur Herstellung von Protein C
DE3678552D1 (de) Verfahren zur herstellung von proteinen unter verwendung von transformierten milchsaeurebakterien.
ATE125298T1 (de) Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression.
DE3782350D1 (de) Rekombinante parvovirus-ra-1-produkte und verfahren zu deren anwendung.
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
DE3574967D1 (de) Verfahren zur herstellung von 3-(4-fluorphenoxy)-propionitril und verfahren zur herstellung von 6-fluor-4-chromanon unter verwendung von 3-(4-fluorphenoxy)-propionitril.
DD267619A3 (de) Verfahren zur herstellung von proteinkonzentraten